Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3

Trial Profile

A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3

Discontinued
Phase of Trial: Phase III

Latest Information Update: 05 Jul 2019

At a glance

  • Drugs Brodalumab (Primary) ; Ustekinumab
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms AMAGINE-3
  • Sponsors Amgen
  • Most Recent Events

    • 05 Jul 2019 Results of post hoc analysis of AMAGINE 2 and 3 trials evaluating efficacy and safety of brodalumab in non-obese vs obese patients with psoriasis published in the British Journal of Dermatology
    • 05 Jun 2019 Results published in the Journal of the American Academy of Dermatology
    • 25 Apr 2019 Post-hoc analysis results presented in the LEO Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top